Skip to main content
Mark Litzow on Muck Rack

Mark Litzow

As seen in: Nature, Wiley Online Library, PLOS Medicine, MDPI, JAMA (The Journal of the American Medical Association), Medscape, Science Magazine, HemOnc Today, Journal of Clinical Oncology, Archives of Pathology and
I am a hematologist, professor of medicine and specialist in blood and marrow transplantation and in the treatment of acute and chronic leukemia
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mark

Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients

|
By Saubia Fathima, Lior Rokach, Nour Ghosoun, Mahsa RezaSoltani, Rimal Ilyas, Ali Alsugair, Kristen B. McCullough, Maymona G. Abdelmagid, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Aasiya Matin, Antoine Saliba, Mehrdad Hefazi Torghabeh, Mark Litzow, William Hogan, Mithun V. Shah, Mrinal Patnaik, Animesh Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Jeanne Palmer, Nathan Punwani, Lisa Sproat, Nandita Khera, Ayalew Tefferi, Naseema Gangat Verified, Cecilia Arana Yi
| Nature Verified
Abstract The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current study, we retrospectively examined outcomes of 600 patients with newly diagnosed AML treated with CPX-351 (N = 112) or Ven-HMA (N = 488).
Open in Who Shared Issue with article?

Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia

|
By Zhenbo Tu, Jaewoong Lee, John Foley Verified, Ruifeng Sun, Kohei Kume, Mark Robinson, Kadriye Nehir Cosgun, Ning Ma, Christian Hurtz, Huimin Geng, Selina M. Luger, Mark Litzow, Elisabeth Paietta, Jianjun Chen, Nagarajan Vaidehi, Markus Müschen, Zhangliang Cheng
| Science Magazine Verified
Editor’s summary Although CD25 is a subunit of the IL-2 receptor on T cells, CD25-expressing cells in the leukemias B-ALL and AML do not respond to IL-2 and are associated with poor clinical outcome. Through experiments with mice and patient-derived xenografts, Lee et al. showed that loss of CD25 in acute leukemia resulted in hyperactive oncogenic tyrosine kinase signaling that reduced cell fitness and leukemic potential.
Open in Who Shared Issue with article?

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia - Bone Marrow Transplantation

|
By Niveditha Ravindra, Jeffery J. Auletta, Firas El Chaer, Steven M. Devine Verified, Mark Litzow, Partow Kebriaei, Jerald P. Radich, Laura Dillon
| Nature Verified
NPM1 mutations (NPM1m), seen in ~30% of adults with acute myeloid leukemia (AML), often co-occur with FLT3 internal tandem duplication (FLT3-ITD) [1, 2]. Measurable residual disease (MRD) testing in first complete remission (CR) identifies patients at high risk of relapse after allogeneic hematopoietic cell transplantation (alloHCT) [3, 4].
Open in Who Shared Issue with article?
See all 38 licensed articles (45 Total)